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Introduction 
Mutations in over 50 genes have been associated with Charcot-Marie-Tooth (CMT) disease. As 
new genes continue to be discovered, the task of sequencing each of them individually with 
traditional techniques becomes increasingly burdensome. In addition, these approaches have 
disadvantages that may reduce their sensitivity. Exome sequencing uses targeted sequence 
capture of exons and next-generation sequencing to evaluate the sequence of all exons 
simultaneously. Here, we report a family with the CMT2C phenotype in whom exome 
sequencing revealed a novel mutation in the transient receptor potential vanilloid 4 (TRPV4) 
gene missed by previous Sanger sequencing.
1 
Methods 
Standard Protocol Approvals, Registrations, and Patient Consents 
Subjects were evaluated after giving written consent to an NINDS Institutional Review Board-
approved protocol. DNA extracted from peripheral blood was sequenced on a Genome Analyzer 
IIx platform (Illumina, CA). Sequence variants were confirmed by Sanger sequencing using 
newly-designed primers. 
Cellular studies  
Calcium imaging and cell death assays were performed using transiently-transfected HEK293 
cells as previously described.
1 Statistical significance was determined using two-tailed unpaired 
t-tests. 
 
Results 
Exome sequencing reveals a novel mutation in a family with CMT2C        Neurology #2011/409300 
We evaluated nine family members (figure, A), three of whom exhibited features consistent with 
the CMT2C phenotype,
1,2 including progressive distal limb muscle weakness and atrophy, 
hoarseness of voice, and stridor on exertion (Supplemental Table). Nerve conduction studies 
confirmed an axonal neuropathy with phrenic nerve involvement; laryngoscopy showed 
reductions in vocal fold opening and closing. Two individuals had scoliosis, but skeletal 
dysplasia was not evident on bone radiographs. One individual had bilateral sensorineural 
hearing loss.  
Previous Sanger sequencing failed to identify TRPV4 mutations in this family (figure, B), 
designated Family 3.
1 In the present study, we performed exome sequencing in one affected 
individual and, surprisingly, identified a novel sequence variant (c.557G>A) in TRPV4. No 
significant variants were identified in other CMT-causing genes. A review of the Sanger 
sequencing primers used to amplify this region of TRPV4 revealed that the forward and reverse 
primers each contained a single nucleotide polymorphism (SNP). Further Sanger sequencing 
with newly-designed primers revealed the c.557G>A sequence change in all three individuals 
with CMT2C, but not in the six unaffected individuals (figure, B), nor in 200 controls. This 
nucleotide change results in an arginine to glutamine substitution at amino acid 186 (R186Q), a 
highly conserved residue of the TRPV4 protein (figure, C), a calcium-permeable cation channel. 
Like previously described neuropathy-causing TRPV4 mutations, R186 is an exposed arginine 
residue situated on the convex face of the TRPV4 ankyrin repeat domain (ARD) (figure, D),
1,2 a 
domain mediating regulatory interactions.
3    
 
Expression of R186Q-TRPV4 causes cellular toxicity        Neurology #2011/409300 
Neuropathy-causing TRPV4 mutations (e.g. R269C) have been shown to increase TRPV4 
channel activity, leading to elevated intracellular calcium levels and cellular toxicity.
1 Here, we 
examined HEK293 cells expressing wild-type (WT), R186Q and R269C forms of TRPV4. As 
previously reported, cells expressing R269C-TRPV4 showed significantly increased basal 
calcium levels (figure, E) and cellular toxicity (figure, F; Supplemental Figure) compared to cells 
expressing WT-TRPV4. Cells expressing R186Q-TRPV4 showed a slight increase in calcium 
levels at 24 hours and significantly increased cell death at 36 hours (figure, E and F; 
Supplemental Figure). Both effects were completely abrogated by the TRP channel antagonist 
ruthenium red (figure, E and F) suggesting the R186Q mutation increases constitutive TRPV4 
activity.  
 
Discussion 
CMT2C and forms of distal spinal muscular atrophy are caused by dominant missense mutations 
in TRPV4.
1,2,4-6 TRPV4 mutations also cause forms of autosomal dominant skeletal dysplasia.
7 
Here, we report a novel TRPV4 mutation in a family with the CMT2C phenotype and no 
evidence of skeletal dysplasia. The localization of the R186Q substitution to the convex face of 
the TRPV4 ARD, a face on which skeletal dysplasia-causing mutations have not been described, 
provides further evidence that this region is of particular importance to TRPV4 function in the 
peripheral nervous system. Importantly, this mutation was not initially detected by traditional 
Sanger sequencing, but was identified by exome sequencing, a technology being used 
increasingly to detect mutations in Mendelian diseases. The initial Sanger sequencing primers 
used to amplify the relevant TRPV4 genomic region overlie known SNPs that may be in linkage 
disequilibrium with the mutation, likely leading to monoallelic amplification of the WT allele.        Neurology #2011/409300 
Exome sequencing technology uses multiple sequence alignments of the same gene fragment, 
thus avoiding the false negatives that can be encountered during Sanger sequencing.  
The identification of the R186Q mutation in TRPV4 by exome sequencing both highlights the 
importance of the ARD in TRPV4 function in the peripheral nervous system and emphasizes the 
advantages of rapidly emerging sequencing technologies. 
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Figure legend 
A family with CMT2C has a novel mutation in TRPV4. (A) Pedigree of the family showing 
vertical transmission of the disease (white=unaffected, black=affected, *DNA collected). (B) 
Chromatographs showing the c.557G>A mutation initially missed by Sanger sequencing and 
later identified by exome sequencing in an affected individual. This sequence variant was not 
apparent using the original primers (top; the “A” variant peak is comparable to the background 
noise), but became clearly visible when primers that do not contain SNPs were used to amplify 
the genomic DNA (middle). The sequence variant is not present in unaffected individuals 
(bottom). (C) The R186 residue in TRPV4 is highly conserved across a wide range of species. 
(D) Like previously described neuropathy-causing TRPV4 mutations, the R186 residue is 
situated on the convex face of the TRPV4 ARD. In contrast, those skeletal dysplasia mutations 
occurring in the TRPV4 ARD localize to its concave face (at left: green=neuropathy mutations; 
at right: yellow=neuropathy mutations, green=skeletal dysplasia mutations). (E) Basal calcium 
levels are modestly increased in HEK293 cells expressing R186Q-TRPV4 and significantly 
increased in cells expressing R269C-TRPV4,
 compared to cells expressing WT-TRPV4
 for 24 
hours. The TRP channel antagonist ruthenium red completely blocks this calcium influx 
(*p=0.05, n=8 per group). (F) Approximately 10 % of cells expressing R186Q-TRPV4
 and 15 % 
of cells expressing R269C-TRPV4 compared to approximately 5 % of cell expressing WT-
TRPV4
 were dead at 36 hours post-transfection (*p=0.01, n=3 per group). Treatment with 
ruthenium red completely blocked cellular toxicity. Cells were incubated with 2 µM calcein AM 
and 4 µM EthD-1 for 30 minutes at room temperature and the percentage of dead cells calculated 
using a Zeiss AxioImager Z1 microscope and AxioVision 4.6 software. AC
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Supplemental Figure.  Cells expressing mutant R186Q TRPV4 show increased rates of cell death. 
In cell death assay#2 (see Methods), approximately 14% of cells expressing R186Q TRPV4 and 
19% of cells expressing R269C TRPV4 compared to approximately 6% of cell expressing WT 
TRPV4 were dead at 36 hours (*p=0.01, n=6 per group).